{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-027398","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2023-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.454889+00:00","generated_at":"2026-06-12T06:18:45.816051+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Foghorn Therapeutics Q2 net loss $29.5M; cash $284.3M; AML combo study starting Q3 2023","bullets":["Net loss of $29.5M for Q2 2023 vs $27.3M in Q2 2022.","Cash, cash equivalents & marketable securities of $284.3M, providing runway into H2 2025.","Collaboration revenue $5.6M (up from $4.5M YoY), primarily from Lilly agreement.","FHD-286 combination study in AML to begin Q3 2023 after resolving clinical hold.","Pipeline advancing: selective BRM, ARID1B, EP300, CBP programs toward IND; six new INDs targeted in 4 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-027398","json":"https://secwatch.observer/filing/0001628280-23-027398.json","markdown":"https://secwatch.observer/filing/0001628280-23-027398.md","text":"https://secwatch.observer/filing/0001628280-23-027398.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828023027398/0001628280-23-027398-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828023027398/fhtx-20230804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T06:18:45.816051+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bd65e26cc7602efda729d65d2e15d6aba68110ed","claim":"Foghorn Therapeutics Inc. reported the quarter ended June 30, 2023 results: revenue $5.6 million, net income $29.5 million.","evidence_excerpt":"Collaboration revenue was $5.6 million for the three months ended June 30, 2023, compared to $4.5 million for the three months ended June 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828023027398/0001628280-23-027398-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$5.6 million"},{"label":"Net income","value":"$29.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}